icon-folder.gif   Conference Reports for NATAP  
 
  64rd Annual Meeting of the
American Association for the
Study of Liver Diseases
Washington, DC Nov 1-5 2013
Back grey_arrow_rt.gif
 
 
 
Rapid and Consistent Virologic Responses in a Phase 2 Trial of a New All-Oral Combination of Faldaprevir, Deleobuvir and PPI-668, with and without Ribavirin, in Patients with HCV Genotype-1a Infection
 
 
  Reported by Jules Levin
64th Annual Mtg of the American Association for the Study of Liver Diseases,
Washington DC, Nov 1-5 2013 Wash DC
 
J. Lalezari1, L. Holland1, E. Glutzer1, P. Vig2, M. Elgadi3, J.O. Stern3, R. Colonno2, S. Halfon2, E. Ruby2, N. Huang2, Q. Huang2, E. Nash2 and N. Brown2 1Quest Clinical Research and U. California-San Francisco (San Francisco, CA, USA), 2Presidio Pharmaceuticals (San Francisco, CA, USA), 3Boehringer Ingelheim Pharmaceuticals (Ridgefield, CT, USA)

HIV1.gif

HIV2.gif

HIV3.gif

HIV4.gif

HIV5.gif

HIV6.gif

HIV7.gif

HIV8.gif

HIV9.gif